ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.549_550del (p.His183fs)

dbSNP: rs730881297
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000159626 SCV000209613 pathogenic not provided 2014-08-27 criteria provided, single submitter clinical testing This deletion of 2 nucleotides in ATM is denoted c.549_550delTA at the cDNA level and p.His183GlnfsX6 (H183QfsX6) at the protein level. The normal sequence, with the bases that are deleted in brackets, is TTCA[TA]GAGT. The deletion causes a frameshift, which changes a Histidine to a Glutamine at codon 183, and creates a premature stop codon at position 6 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. we consider this variant to be pathogenic.The presence of
Invitae RCV000471869 SCV000546981 pathogenic Ataxia-telangiectasia syndrome 2023-11-15 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.His183Glnfs*6) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with colon cancer (PMID: 26681312). ClinVar contains an entry for this variant (Variation ID: 181868). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000572101 SCV000667976 pathogenic Hereditary cancer-predisposing syndrome 2022-03-15 criteria provided, single submitter clinical testing The c.549_550delTA pathogenic mutation, located in coding exon 5 of the ATM gene, results from a deletion of two nucleotides at nucleotide positions 549 to 550, causing a translational frameshift with a predicted alternate stop codon (p.H183QFS*6). This alteration was identified in 1/10030 patients referred for hereditary cancer panel testing (Susswein LR et al. Genet. Med., 2016 Aug;18:823-32). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Baylor Genetics RCV003462066 SCV004216238 likely pathogenic Familial cancer of breast 2021-05-25 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003462066 SCV004930634 pathogenic Familial cancer of breast 2024-01-09 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.